首页> 外文OA文献 >Hypofractionated Radiotherapy Dose Scheme and Application of New Techniques Are Associated to a Lower Incidence of Radiation Pneumonitis in Breast Cancer Patients
【2h】

Hypofractionated Radiotherapy Dose Scheme and Application of New Techniques Are Associated to a Lower Incidence of Radiation Pneumonitis in Breast Cancer Patients

机译:低抗疗法的放射治疗剂量方案和新技术的应用与乳腺癌患者的辐射肺炎发病率较低有关

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Purpose: Radiation pneumonitis (RP) is one of the most severe toxicities experienced by patients with breast cancer after radiotherapy (RT). RT fractionation schemes and techniques for breast cancer have undergone numerous changes over the past decades. This study aimed to investigate the incidence of RP as a function of such changes in patients with breast cancer undergoing RT and to identify dosimetric markers that predict the risk of this adverse event.Methods and Materials: We identified 1,847 women with breast cancer who received adjuvant RT at our institution between 2015 and 2017. The RT technique was individually tailored based on each patient's clinicopathological features. Deep inspiration breath hold technique or prone positioning were used for patients who underwent left whole-breast irradiation for cardiac sparing, while those requiring regional lymph node irradiation underwent volumetric-modulated arc therapy (VMAT).Results: Of 1,847 patients who received RT, 21.2% received the conventional dose scheme, while 78.8% received the hypofractionated dose scheme (mostly 40 Gy in 15 fractions). The median follow-up period was 14.5 months, and the overall RP rate was 2.1%. The irradiated organ at risk was corrected concerning biologically equivalent dose. The ipsilateral lung V30 in equivalent dose in 2 Gy (EQD2) was the most significant dosimetric factor associated with RP development. Administering RT using VMAT, and hypofractionated dose scheme significantly reduced ipsilateral lung V30.Conclusions: Application of new RT techniques and hypofractionated scheme significantly reduce the ipsilateral lung dose. Our data demonstrated that ipsilateral lung V30 in EQD2 is the most relevant dosimetric predictor of RP in patients with breast cancer.
机译:用途:放射性肺炎(RP)是放射治疗(RT)后乳腺癌患者经历的最严重的毒性反应之一。 RT分级方案和乳腺癌技术已经历了过去几十年许多变化。本研究旨在探讨RP的发病率在透析患者RT这样的变化与乳腺癌的作用,并确定预测这种不利event.Methods和材料的风险剂量学标志物:我们确定了1847名乳腺癌患者谁接受辅助RT在我们2015年和2017年之间的制度RT技术是单独定制根据每个患者的临床病理特征。深吸气呼吸保持技术或俯卧位被用于谁接受左全乳照射用于心脏备用的患者,而那些需要区域性淋巴结照射后行容积调制弧治疗(VMAT)。结果:谁收到RT 1847名患者中,21.2 %接受常规剂量方案,而78.8%收到的大分割剂量方案(主要是40 Gy的在15个级分)。中位随访期为14.5个月,总RP率为2.1%。在风险照射器官已得到纠正有关生物等效剂量。在2戈瑞(EQD2)等效剂量同侧肺V30是与RP发展相关联的最显著剂量学因素。施用RT使用VMAT,和大分割剂量方案显著降低同侧肺V30.Conclusions:新的RT技术和大分割方案应用显著减少同侧肺剂量。我们的数据显示,EQD2患侧肺V30是RP的乳腺癌患者最相关的剂量学的预测。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号